The collaboration's initial phase involves a technical feasibility study, relying on Framatome's successful isotopes production technology, previously implemented in Canada. The focus is on maximizing Cernavoda's existing infrastructure to produce medical isotopes, alongside its primary function of generating reliable, low-carbon electricity.
Lutetium-177, the focal point of this agreement, is a beta-emitting radioisotope increasingly used in targeted radionuclide therapy. It has shown promising results in the treatment of prostate cancer and is being explored for other cancer indications. Its ability to selectively destroy cancer cells while minimizing damage to healthy tissue makes it a valuable asset in the fight against cancer.
Francois Gauche, Director of Framatome Healthcare, expressed enthusiasm about the project. He stated, "Mass access to nuclear medicine is closely linked to the development of large-scale, reliable, and diversified supply chains, and we want to play our part in the fight against cancer by helping build these supply chains." Gauche also emphasized the need for regional nuclear medicine production hubs, viewing this project as a crucial step in strengthening the supply chain in Europe.
Cosmin Ghita, CEO of Nuclearelectrica, highlighted the broader benefits of the partnership. "This partnership is a significant step to help improve the health of millions of people and demonstrate the multiple benefits of nuclear power plants, which generate clean energy, contribute to energy stability, decarbonization, and economic growth," he declared.
Teodor Chirica, President of the Board at Nuclearelectrica SA, also shared his excitement about collaborating with Framatome, noting the potential to showcase the benefits of nuclear energy beyond clean energy production.
Framatome's proprietary isotope production technology enabled the first large-scale commercial production of Lutetium-177 in a power reactor in June 2022, demonstrating the company's leadership in this field. The Cernavoda nuclear power plant, with its 27 years of operational experience and involvement in strategic projects, is well-positioned to support this innovative endeavor.
Framatome Healthcare, dedicated to advancing healthcare solutions, plays a crucial role in this initiative. The division focuses on developing products and services for the healthcare industry, including supporting the radioisotopes value chain used in radiopharmaceuticals for both diagnostic imaging and therapeutic purposes.
Related Links
Framatome
Nuclear Power News - Nuclear Science, Nuclear Technology
Powering The World in the 21st Century at Energy-Daily.com
Subscribe Free To Our Daily Newsletters |
Subscribe Free To Our Daily Newsletters |